Key facts
- Leaderna Therapeutics’s last known valuation is $33.9M (Dec 2022).
- It has raised $44.9M; the latest was Early Stage VC ($21.8M) in Mar 2026.
- Notable investors include CAS Star, CDH Investments, Sky9 Capital, Chengdu Venture Capital Group, Tianjin Venture Capital — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Leaderna Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Leaderna Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Leaderna Therapeutics
Developer of nucleic acid-based therapeutic research designed to advance targeted biological interventions. The company offers project development in nucleic acid modalities, platform-driven investigation of drug candidates, and technical expertise spanning design, modification, and evaluation of oligonucleotide constructs, enabling researchers and biotechnology organizations to pursue precise therapeutic targets and enhance experimental reliability.
- Sector
- Healthcare
- HQ
- Chengdu, China
- Founded
- 2022
- Employees
- 16
- Website
- leadernatx.com/
- Ownership
- Privately Held (backing)
Leaderna Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Leaderna Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Leaderna Therapeutics in its N-PORT filings yet. We sweep new filings monthly.